Table 2.

Mean percentage of sites with PD < 5mm or ≥ 5mm at baseline, and at 2 and 6 months post-treatments. Subjects in the SRP and SRP+PPC groups rinsed with placebo.

		Treatment groups
Percentage of sites with:	Time point	SRP	SRP + PPC	SRP + CHX
	Baseline	64.8 ± 17.1^a	68.6 ± 16.2 ^a	69.8 ± 9.0 ^a
PD < 5mm	2 months*	83.8 ± 9.3 ^{b, A}	87.9 ± 13.0 ^{b, A}	93.3 ± 3.0 ^{b, B}
	6 months*	83.7 ± 9.6 ^{b, A}	89.9 ± 12.8 ^{b, B}	94.7 ± 1.7 ^{b, C}
	Baseline	35.2 ± 17.2 ^a	31.4 ± 16.2 ^a	30.2 ± 9.0 ^a
PD ≥ 5mm	2 months*	16.2 ± 9.3 ^{b, A}	12.1 ± 13.0 ^{b, A}	6.7 ± 3.0 ^{b, B}
	6 months*	16.3 ± 9.2 ^{b, A}	10.1 ± 7.2 ^{b, B}	5.3 ± 1.6 ^{b, C}

The significance of differences among groups was assessed using the Kruskal-Wallis test (* p<0.05), and within pairs of groups was assessed using the Mann-Whitney U-test (different capital letters indicate p<0.05). The significance of differences among time points was assessed using the Friedman test (different small letters indicate p<0.05). Δ 6 months: mean changes between baseline and 6 months post-treatments; SRP: scaling and root planning; PPC: professional plaque control; CHX: chlorhexidine digluconate; PD: probing depth.